Several compounds have been proposed for overcoming ovarian cancer chemoresistance, including bortezomib [4], antiprogestin compounds [5], combined treatment with death ligand TRAIL and antidiabetic acting PPARγ ligands [6], P-glycoprotein (P-gp) inhibitors [7, 8], cancer stem cell targeting agents and autophagy based modulation [7]. The gene discussed is PPARG; the disease is ovarian cancer.